Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
Date:9/22/2011

m its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the Food and Drug Administration and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release. PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Statement of Operations(unaudited)Quarter Ended June 30, Year Ended June 30,2011201020112010REVENUESLicense and contract

$
24,691$
74,957$
497,540$ 14,180,727Grants

131,149-977,917-Total revenues

155,840674,9571,475,45714,180,727OPERATING EXPENSES:Research and development

3,217,3853,554,52110,377,01912,293,910General and administrative

1,525,0261,374,3204,751,8244,901,203Total operating expenses

4,742,4114,928,84115,128,84317,195,113Loss from operations

(4,586,571)(4,253,884)(13,653,386)(3,014,386)OTHER INCOME (EXPENSE):Investment income

26,91621,36599,258141,635Interest expense

(4,999)(3,862)(10,606)(13,165)Decrease/(increase) in fair value of warrants

1,255,425-(2,266)-Gain on sale of securities

--119,346-Gain/(loss) on disposition of supplies and equipment

--(5,666)95,000Total other income, net

1,277,34217,503200,066223,470Loss before income taxes

(3,309,229)(4,236,381)(13,453,320)(2,
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 On January, 14, 2015, ... Washington D.C. science community to the UMBC campus for ... by the Protein Society, will take place from 9 ... 312. Through discussion, presentations and workshops, the free ... proteins, their role in the industry and the future ...
(Date:11/26/2014)... Sunnyvale, CA (PRWEB) November 25, 2014 ... joins forces with RPM Alliance , provider ... and pharmaceutical companies. With the latest addition to its ... only free validated EDC system to India. , ... as a robust and customizable EDC platform which is ...
(Date:11/26/2014)... November 26, 2014 SoundConnect , ... is proud to announce that Darren Suders has joined ... Darren will drive the partner program ... experience. , Darren brings more than 10-years ... key roles in channel operations, from policy development, to ...
(Date:11/26/2014)... 25 novembre 2014 /PRNewswrie/ -- Theravalues Corporation annuncia con ... europeo in occasione di Hi Europe 2014 (dal 2 ... Si tratta della curcumina con la maggiore biodisponibilità ... cristalli) e ingredienti approvati dalle norme europee. ... della pianta curcumina ( Curcuma longa ) che è ...
Breaking Biology Technology:RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3
... 7 Transgenomic Inc. (OTC,Bulletin Board: TBIO) announces the following Webcast: What: ... Conference Call, When: ... Where: http://www.transgenomic.com/events.asp?id=6 , How: ... the address ...
... CA, Nov. 7 /PRNewswire-FirstCall/ - Nventa,Biopharmaceuticals Corporation (TSX: NVN) ... 30, 2007. All amounts, unless,specified otherwise, are in Canadian ... million or $0.01 per share, for the,three months ended ... $2.3,million, or $0.03 per share, for the same period ...
... BioSpace, the leading biotech job,board and life ... pharmaceutical job seekers to the BioSpace Career Fair ... BioSpace Career Fair attracted a steady flow of ... from around the Maryland biotechnology cluster and Mid-Atlantic,region. ...
Cached Biology Technology:Webcast Alert: Transgenomic Inc. Announces Third Quarter 2007 Earnings Release Conference Call Webcast 2Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results 2Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results 3Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results 4BioSpace Career Fair in Bethesda, Maryland Draws Hundreds of Industry Professionals 2
(Date:11/11/2014)... 11, 2014  Forensicon, Inc., a Chicago ... to announce the promotion of Yaniv Schiff ... Forensics. In Schiff,s new role as Director, he will ... digital forensics examiners and provide leadership within the company,s ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon ...
(Date:11/7/2014)... BURBANK, Calif. , Nov. 7, 2014  In conjunction ... Burbank Police Departments, The Community Foundation of the ... BURBANK DNA JUSTICE PROJECT," a $250,000 initiative to ... successful initial phase. In its first six months of existence, ... desperately needed evidence support for local law enforcement. ...
(Date:11/6/2014)... metastasis, yet progress in preventing and treating migratory ... particularly challenging to design drugs that work against ... biology at Harvard Medical School. , "Unfortunately, ... metastasized." , Gujral and colleagues have now identified ... understand how metastasis begins. Their findings may also ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Migration negation 2Migration negation 3
... Scientists have moved closer to developing a universal flu vaccine ... study why some people seem to resist severe illness. ... samples just as the swine flu pandemic was getting underway ... flu seasons. They found that those who avoided severe ...
... several stages -- first by invading surrounding tissue, then ... circulating cells work their way out of the vascular ... initial process by which cancer cells enter the bloodstream ... escape blood vessels to permeate other tissues and organs ...
... study published in The Journal of Comparative Neurology ... science Michael Ariel, Ph.D., reported surprising findings about the ... head deep into their shell. While researchers expected ... animals with eyes on the side of their heads, ...
Cached Biology News:Scientists closer to universal flu vaccine after pandemic 'natural experiment' 2Microfluidic platform gives a clear look at a crucial step in cancer metastasis 2Microfluidic platform gives a clear look at a crucial step in cancer metastasis 3SLU researcher finds a turtle eye muscle adapts to deal with obstructed vision 2
... system for fluorescent light due to small ... camera to detect low level light in ... disease research, gene expression, circadian rhythm, gels ... imager with a motor-driven camera inside the ...
Mouse polyclonal antibody raised against a partial recombinant TSEN2. NCBI Entrez Gene ID = 80746...
Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B...
...
Biology Products: